KLOW Peptide Blend: Ingredients, Legal Status and Risks

Legal status of KLOW

Not allowed in compounding

KLOW is a marketing name for a peptide blend, and the only source we found on its contents is low confidence ^[1]. None of its reported ingredients can be legally compounded for injection today ^[2].

FDA status

The only source we found that defines KLOW is a consumer health guide, so treat its contents as low confidence ^[1]. That guide says KLOW combines GHK-Cu, BPC-157, TB-500 and KPV, and that no human trial has tested it ^[1]. A compounded blend would need every ingredient to be lawful. None of these four is eligible for 503A compounding in injectable form as of Oct 19, 2026 ^[2]. Removal of BPC-157, TB-500, KPV and injectable GHK-Cu from Category 2 in April 2026 did not make them legal to compound ^[11].

Advisory committee

On July 23, 2026, the committee voted 8-6-1 to recommend BPC-157, TB-500 and KPV ^[8]. These votes are recommendations that do not bind FDA ^[9]. Injectable GHK-Cu is still waiting for a review planned before the end of February 2027 ^[2].

FDA-approved products

None. We found no FDA-approved drug that contains any of the reported ingredients.

Sports (WADA)

Two of the reported ingredients are named on the 2026 list: BPC-157 under class S0 and TB-500 under class S2 ^[10].

What happens next

FDA would have to make every ingredient lawful to compound. For BPC-157, TB-500 and KPV that means rulemaking or another formal step after the July votes ^[9], and injectable GHK-Cu still needs its committee review ^[2]. FDA had not acted on any of them as of Oct 16, 2026 ^[12].

Checked against FDA sources on Oct 19, 2026. We update this box when FDA acts. Report a change: [email protected].

What KLOW and the Wolverine blend are said to contain

KLOW is a name used to sell a peptide blend, not a drug name. We found one source that defines it that is not a seller: a consumer health guide from Superpower, which says it does not sell the blends. That guide says KLOW combines GHK-Cu, BPC-157, TB-500 and KPV, that the related GLOW blend has the first three without KPV, and that "no human trial has tested either blend" ^[1]. Because we found no primary source, such as a drug filing or a published study, we treat the contents as low confidence. Search results for KLOW are otherwise mostly sellers, which we do not cite or link.

The "Wolverine" stack is a two-peptide version: BPC-157 plus TB-500. Healthline says the pair has been dubbed the "Wolverine" stack for its supposed regenerative effects, and notes the combination "isn't approved by the FDA and hasn't been tested in humans for safety or effectiveness" ^[3].

Whatever a label says, nothing about the contents of a KLOW vial has been checked by FDA, because no KLOW product has gone through any FDA review ^[2].

Is KLOW legal?

No. There is no FDA category for blends. A compounded blend would need every ingredient to be lawful for compounding, and none of the four is, in injectable form, as of Oct 19, 2026 ^[2]. FDA took BPC-157, TB-500, KPV and injectable GHK-Cu out of Category 2 in April 2026 because the nominators withdrew ^[17], but that removal "does not render these bulk drug substances eligible for compounding," as Frier Levitt put it ^[11].

Legal status of each reported KLOW ingredient, checked Oct 19, 2026

Ingredient	Can a pharmacy compound it for injection?	Advisory committee	Human data FDA found	WADA 2026
BPC-157	No. Not in Category 1 or on the 503A bulks list [2]	Voted 8-6-1 in favor on July 23, 2026; nonbinding [8] [9]	Five small studies; FDA could not describe its safety profile [4]	Banned, class S0 [10]
TB-500	No [2]	Voted 8-6-1 in favor on July 23, 2026; nonbinding [8] [9]	No clinical studies, no human drug level data, no published case reports [5]	Banned, class S2 [10]
KPV	No [2]	Voted 8-6-1 in favor on July 23, 2026; nonbinding [8] [9]	No clinical trials or human drug level data; lab and animal data only [6]	Not named [10]
GHK-Cu (injectable)	No. Creams and other non-injectable forms are Category 1 [2]	Review planned before the end of February 2027 [2]	Limited human data; FDA cites immune reaction risk [7]	Not named [10]

Three ingredients won a favorable but nonbinding committee vote in July 2026. FDA must still act through rulemaking or another formal step, and one law firm says there is no reliable timetable ^[9]. HHS has sent an interim peptide access policy to the White House budget office ^[12]. The AP, citing two unnamed people, reported it is meant to cover some of the most popular peptides, including BPC-157 ^[18]; the policy has not been issued, and Holland & Knight says its details remain to be seen ^[12]. Injectable GHK-Cu has not had its committee review yet ^[2]. The full list is on our peptide FDA status tracker.

Why a blend adds risk

• No ingredient has passed FDA review as a drug. We found no FDA-approved drug containing any of the four ^[2].
• The combination is untested. No human trial has tested KLOW or GLOW, according to the one guide that defines them ^[1].
• FDA's own data on blends is thin. FDA's search of its Human Foods Complaint System for its TB-500 review found two reports about "blended TB-500 and BPC-157," and the reports did not include safety assessments ^[5].
• Each ingredient brings its own concerns. FDA flags a possible significant immune reaction risk for BPC-157 ^[4] and immune reaction risk with limited human data for injectable GHK-Cu ^[7]. For TB-500, FDA found "a lack of clinical and nonclinical safety information" ^[5]. For KPV, FDA is "particularly concerned about the lack of any human data" ^[6].
• Interactions are unknown. When the single ingredients have little human data, there is no basis for knowing how they behave together.

KLOW side effects

We found no side effect data for KLOW or for any blend of these peptides. The single ingredients do not fill the gap: FDA wrote that there is insufficient clinical safety information to characterize the safety profile of BPC-157 ^[4], and it found no clinical studies or published case reports for TB-500 ^[5] and no human data for KPV ^[6]. Any list of KLOW side effects on a seller site is not drawn from controlled studies.

Enforcement and use

Labeling a blend "research use only" does not make it legal to sell for people. FDA rejected that label in a Feb 26, 2025 warning letter to USApeptide.com ^[13]. In April 2026, federal prosecutors in Utah indicted a physician on charges of receiving misbranded drugs from China, including BPC-157, TB-500 and GHK-Cu, and giving them to more than 200 patients; those are allegations, and he is presumed innocent ^[14]. More cases are in our FDA warning letter list.

Use is growing. Reuters reported in September 2026 on an analysis of more than 15 million US medical records that found 1,039 patients with documented BPC-157 use and a 33-fold rise in new confirmed users from 2020 to 2026; the analysis had not been peer reviewed ^[15].

KLOW and drug testing in sports

Two of KLOW's reported ingredients are banned by name on the 2026 WADA Prohibited List: BPC-157 under class S0 and TB-500 under class S2, which names "Thymosin-ß4 and its derivatives e.g. TB-500" ^[10]. A product containing either would put a tested athlete at risk of a violation.

Copper peptide creams are a different product

GHK-Cu is legal in one form. Non-injectable GHK-Cu, such as a cream, is in FDA's Category 1, so a 503A pharmacy may compound it for a patient with a prescription ^[2]. Skin care serums that list copper peptides are also sold over the counter as cosmetics ^[16]. Neither is the same as injecting GHK-Cu in a blend. Prices for the legal forms are in our legal peptide price tracker.

How to get KLOW legally

If you are looking at KLOW for an injury, skin or recovery, a doctor can talk through FDA-approved treatments for the specific problem. Approved peptide drugs exist for narrow uses, such as tesamorelin for HIV-related belly fat. See also our wellness injections guide.

What changed for KLOW

Newest first.

• Jul 23, 2026: The advisory committee voted 8-6-1 to recommend BPC-157, TB-500 and KPV. The votes are not binding ^{[8] [9]}.
• Apr 15, 2026: FDA gave notice it would remove BPC-157, TB-500, KPV and injectable GHK-Cu, among others, from Category 2 ^[17].

How we check

We check each ingredient against FDA's 503A categories document and FDA's briefing documents, confirm committee votes in at least two outside reports because FDA has not posted its own July 2026 minutes, and read the 2026 WADA list. We do not cite or link sellers. If a primary source defining KLOW appears, we will replace the low-confidence guide. Status last checked Oct 19, 2026. Our method: editorial standards.